Diagnosis and Management of von Willebrand Disease in Iran

 

 Buy Article Permissions and Reprints

ABSTRACT

Little information is available on von Willebrand disease (VWD) in Iran. More than 900 patients with VWD are registered, but the real number of patients with VWD is likely to be larger. Fifteen hemophilia treatment centers in addition to 31 other academic centers are the main sites for the clinical management and treatment of VWD in Iran. All centers are staffed by specialists in the medical care of VWD. Epistaxis and menorrhagia are the most frequent clinical manifestations in Iranian patients with VWD. von Willebrand factor/factor VIII concentrates, desmopressin, cryoprecipitates, and tranexamic acid are the main medications used routinely in Iranian patients, and they are administered based on the type of disease, the severity of bleeding, and sometimes for the prevention of bleeding during surgical procedures or delivery. It is hoped that the recent creation of a national registry for coagulation disorders and improvements in laboratory techniques will improve the diagnosis, national patients' registry, and management of VWD in Iranian patients and lead to gains in their quality of life in the near future.

REFERENCES

• 1 Mannucci P M. Treatment of von Willebrand's disease.  N Engl J Med. 2004;  351 (7) 683-694
  Google Scholar
• 2 Sadler J E, Budde U, Eikenboom J C Working Party on von Willebrand Disease Classification et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor.  J Thromb Haemost. 2006;  4 (10) 2103-2114
  Google Scholar
• 3 Dilley A, Drews C, Miller C et al.. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia.  Obstet Gynecol. 2001;  97 (4) 630-636
  Google Scholar
• 4 Shoa'i I, Lavergne J M, Ardaillou N, Obert B, Ala F, Meyer D. Heterogeneity of von Willebrand's disease: study of 40 Iranian cases.  Br J Haematol. 1977;  37 (1) 67-83
  Google Scholar
• 5 Central Intelligence Agency .The World Factbook: Iran. Available at: https://www.cia.gov/library/publications/the-world-factbook/geos/ir.html
  Google Scholar
• 6 Lak M, Peyvandi F, Mannucci P M. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease.  Br J Haematol. 2000;  111 (4) 1236-1239
  Google Scholar
• 7 Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels J J. Laboratory diagnosis and molecular classification of von Willebrand disease.  Acta Haematol. 2009;  121 (2-3) 71-84
  Google Scholar
• 8 Yawn B, Nichols W L, Rick M E. Diagnosis and management of von Willebrand disease: guidelines for primary care.  Am Fam Physician. 2009;  80 (11) 1261-1268
  Google Scholar
• 9 Shahbazi S, Mahdian R, Ala F A, Lavergne J M, Denis C V, Christophe O D. Molecular characterization of Iranian patients with type 3 von Willebrand disease.  Haemophilia. 2009;  15 (5) 1058-1064
  Google Scholar
• 10 Baronciani L, Cozzi G, Canciani M T et al.. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients.  Blood Cells Mol Dis. 2003;  30 (3) 264-270
  Google Scholar
• 11 University of Sheffield; International Society on Thrombosis and Haemostasis .International Society on Thrombosis and Haemostasis Science Standardization Committee von Willebrand Disease database. Available at: http://www.vwf.group.shef.ac.uk
  Google Scholar
• 12 Gill J C, Ewenstein B M, Thompson A R, Mueller-Velten G, Schwartz B A. Humate-P Study Group . Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy.  Haemophilia. 2003;  9 (6) 688-695
  Google Scholar
• 13 Karimi M, Ghavanini A A. Seroprevalence of HBsAg, anti-HCV, and anti-HIV among haemophiliac patients in Shiraz, Iran.  Haematologia (Budap). 2001;  31 (3) 251-255
  Google Scholar
• 14 Federici A B, Mazurier C, Berntorp E et al.. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study.  Blood. 2004;  103 (6) 2032-2038
  Google Scholar
• 15 Boda Z, Pfliegler G, Hársfalvi J, Rak K. Treatment of the severe bleeding episode in type III von Willebrand's disease by simultaneous administration of cryoprecipitate and platelet concentrate.  Blood Coagul Fibrinolysis. 1991;  2 (6) 775-777
  Google Scholar
• 16 Mannucci P M. Hemostatic drugs.  N Engl J Med. 1998;  339 (4) 245-253
  Google Scholar
• 17 Kadir R A, Lee C A, Sabin C A, Pollard D, Economides D L. Pregnancy in women with von Willebrand's disease or factor XI deficiency.  Br J Obstet Gynaecol. 1998;  105 (3) 314-321
  Google Scholar

Mehran KarimiM.D. 

Professor of Pediatric Hematology-Oncology, Hematology Research Center

Nemazee Hospital, Shiraz, Iran

Email: karimim@sums.ac.ir